Brickell biotech, inc. (VICL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-

-

-

-

-

-

-

-4,868

-6,270

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-4,100

-

-

-

-4,580

-

-

-

-

-

-

-

-2,824

-

-2,523

-1,255

-2,423

-2,355

-300

-2,762

-3,821

-4,633

-4,364

-4,040

-3,455

-2,192

-9,883

-9,881

-9,282

-7,549

-7,726

-7,868

244

-6,614

16,431

-8,406

-8,694

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

3

-

-

-

12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

-25

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

0

-

-

-

-231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discounts and financing costs

0

-

-

-

101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

55

64

71

196

259

267

281

280

279

277

275

289

294

301

333

390

473

467

482

534

577

620

637

710

488

493

761

587

580

579

Accretion of discount on short-term investments

-

-

-

-

-

-

-

-46

-24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of abandoned patents

-

-

-

-

-

-

-

406

267

0

0

0

0

0

3

8

363

180

4

0

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

2

6

-

-

-

-

Net gain on sale of long-term investment

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of abandoned patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

20

-

-

-

-

Stock-based compensation

403

525

1,003

-380

384

195

307

162

47

145

183

197

231

186

213

278

313

368

437

526

571

-

-

-

-

-

-

816

1,138

-

735

923

920

-

-

-

-

Write-off of abandoned patents and licensed technology

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81

-

-

-

-

-

-

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

884

837

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of technology license with common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

775

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-483

-

-

-

-40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-1,108

-

-

-

2,521

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-1,268

-

-

-

-72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred contract costs

-

-

-

-

-

-

-

-

-

928

1,127

1,284

1,650

1,901

1,845

1,567

115

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables and other assets

-

-

-

-

-

-

-

-203

-3,679

2,292

-6

166

-479

785

-151

-976

-498

-408

1,073

799

-469

-511

158

154

-213

-

-

-

-

-

-

-

-

-

-

-

-

Compensation expense related to stock options and awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

747

815

798

Receivables and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-307

238

-

-1,240

-9,765

10,412

487

1,580

-581

437

Accounts payable and accrued expenses

-

-

-

-

-

-

-

257

-2,315

1,139

298

246

-370

492

754

-374

-315

470

-677

-91

-1,117

585

868

480

-298

-1,686

-827

860

-535

24

512

-2,217

889

862

-154

237

-996

Employee termination benefits accrual

-

-

-

-

-

-

-

-166

168

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-1,045

-669

-7,218

3,461

-3,491

-2,476

12,437

-65

-184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

600

1,887

2,298

-

-10

38

-166

-1,860

1,590

490

30

-37

-38

-38

-37

113

-38

-92

17

150

0

0

-99

99

-51

-25

76

Deferred rent

-

-

-

-

-

-

-

-

-

0

0

6

217

217

179

118

119

119

108

102

103

102

92

87

87

87

76

72

72

71

62

57

57

57

42

35

35

Net Cash Provided by (Used in) Operating Activities

-6,600

-14,100

-12,392

-4,192

-5,316

-3,654

16,251

-4,062

-4,568

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,543

1,034

-8,008

-4,615

15,938

-6,253

-8,709

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of long-term investment

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,786

-

-3,156

-1,735

-1,687

-1,819

162

-2,442

-2,849

-2,631

-2,375

-2,440

-2,360

-5,435

-8,608

-7,484

-8,271

-

-

-

-

-

-

-

-

Proceeds from the sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,750

-

-

-

-

Maturities of marketable securities

4,500

14,000

-6,500

12,000

0

0

-14,719

7,494

7,225

11,413

7,609

5,928

6,479

11,437

6,793

8,126

4,296

5,153

3,595

7,412

4,023

2,556

150

1,610

6,240

-

-

-

-

-

-

-

-

-

-

-

-

Capital expenditures

0

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

3,454

17,389

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

2,995

3,993

5,187

-

8,067

6,972

10,039

8,550

4,648

2,940

3,912

2,206

9,488

9,145

1,804

-

-

-

-

-

-

-

-

-

-

-

-

Sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

2

6

-

-

-

-

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,692

12,480

-

4,271

4,209

5,261

4,290

6,257

4,906

4,767

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,744

293

-

12,201

9,552

17,659

2,049

5,613

163

16,773

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

53

8

5

14

25

25

114

91

14

25

10

23

42

16

11

16

26

33

109

164

117

96

298

135

-34

88

124

78

Net cash provided by (used in) investing activities

4,500

14,001

10,071

8,440

-2

-4

6,132

4,024

-10,164

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,134

-5,751

-8,874

2,184

452

4,510

-12,186

CASH FLOWS FROM FINANCING ACTIVITIES:
Patent and licensed technology expenditures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

8

15

30

29

52

76

112

36

164

102

110

91

109

112

97

91

104

109

102

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

1,278

-

-1,299

1,040

-5,834

-3,408

-1,086

4,447

58

294

-9,406

-7,622

4,308

5,472

2,020

5,737

11,913

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock and warrants, net of offering cost

1,990

-

-

13

0

-

-

0

1

-

804

308

4

-

7,754

0

5

-

1

0

2

149

2,675

1,101

0

1

435

52

328

2

159

2

48,770

84

107

22

1

Proceeds from the exercise of warrants

15

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory notes

0

-

-

-

1,315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of principal of note payable

0

-

-

-

795

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of withholding taxes for net settlement of restricted stock units

-

-

-

-

-

-

-

-

-

1

1

1

1

1

3

3

7

0

3

4

16

1

27

2

29

12

69

298

103

52

49

43

109

25

40

30

64

Net cash provided by financing activities

2,005

47

2,576

-507

520

-805

-482

-1

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

225

-

110

-41

48,661

59

67

-8

-63

NET DECREASE IN CASH AND CASH EQUIVALENTS

-105

-

-

-

-4,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

3

-

7,751

-3

-2

0

-2

-4

-14

148

2,648

1,099

-29

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-39

-14,731

14,631

2,477

50

-505

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplement Disclosure of Cash Flow Information:
Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-698

-7,523

-

-926

2,001

-2,805

-2,189

-9,133

-8,963

1,919

26

-6,222

-1,993

3,867

-9,991

-12,567

-4,758

31,779

-2,372

16,457

-1,751

-20,958

Interest paid

0

-

-

-

127

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplement Disclosure of Non-Cash Investing and Financing Activities:
Reduction of redeemable convertible preferred stock to redemption value

0

-

-

-

-10,519

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants to purchase common stock issued with convertible promissory notes

0

-

-

-

264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock issuance costs

0

-

-

-

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative liability issued with convertible promissory notes

0

-

-

-

256

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-